BioWorld

July 11, 2005

Sonus, FDA Agree To Terms For Tocosol Paclitaxel SPA

Sonus Pharmaceuticals Inc. is moving forward with pivotal development plans for its lead product, Tocosol Paclitaxel, after completing a special protocol assessment for a single Phase III trial. (BioWorld Today) Read More

Panacea Pharmaceuticals' Series C Round Gets $7M

Money, Experience Drawing Foreign Companies To U.S.

Conforma Gains Synthetic Anthracycline From Japan

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 28, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...